Inhibition of HDAC3, a facilitator of AKT phosphorylation, significantly impeded AML progression and enhanced the susceptibility of MLL-AF9-positive AML cells to chemotherapy (Long et al., 2017). This evidence concerns the gene KMT2A and acute myeloid leukemia.